Latest Healthcare News

Invex Therapeutics has broadened its preclinical Alzheimer's program with Tessara Therapeutics, while its cash reserves dipped to $4.02 million in Q4 FY26 amid increased research and administrative costs.

Genetic Signatures has completed a major restructure delivering $5 million in annual savings from FY2027 and secured a decade-long supply contract with Denmark’s Hvidovre Hospital, while posting $14.8 million revenue for FY2026 amid market pressures.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.

Global Health Limited boosted customer receipts by 12.6% to A$9.53 million for FY26, completing its SaaS platform upgrade and cutting cash burn by 30%. The company targets sustained EBITDA profitability and international expansion in FY27.

Adheris Health’s revenue and profit fell sharply in Q4 FY26 due to the previous challenging pharma budget cycle, but the company achieved cashflow break-even and ended the period with $9.5 million in net cash.

CLINUVEL Pharmaceuticals is relocating its corporate headquarters to the United States and reducing its global workforce by up to 20%, realigning its operations to focus solely on the US pharmaceutical market and unlock greater capital access.

Careteq Limited (ASX: CTQ) has confirmed it will maintain its ASX listing after selling its Embedded Health Solutions subsidiary, shifting its strategic focus entirely to its HMR Referrals platform. The company reported positive operating cash flow in the March quarter and outlined plans to expand its pharmacist and GP networks while exploring AI and adjacent healthcare opportunities.

Artrya has launched its AI-powered Salix platform at Northeast Georgia Health System, marking its second U.S. commercial customer with active revenue streams from subscription and fee-per-scan models.

PolyNovo has delivered solid FY26 revenue growth of 16.1%, driven by commercial sales expansion and improved manufacturing output, while progressing insurance recovery from its R&D centre fire.

Vitrafy Life Sciences has partnered with the historic Hoxworth Blood Center to deploy its next-generation cryopreservation technology, aiming to address a critical gap in red blood cell preservation ahead of legacy technology discontinuation in 2027.

Tissue Repair Limited (ASX: TRP) has applied to delist from the ASX, citing limited liquidity and high listing costs. The company plans a shareholder vote and a $1 million off-market buy-back at a premium to recent prices.

Cambium Bio has raised just over A$1 million through a strategic placement at a 17% premium, boosting a key shareholder’s stake as it advances its pivotal Phase 3 trial for dry eye disease.